Key result
Anti-inflammatory drugs remain the mainstay of treatment for acute and recurrent pericarditis.
Why the study?
Anti-inflammatory treatments for acute and recurrent pericarditis vary in effectiveness and side-effect profile, warranting an up-to-date summary of management.
This review summarizes the up-to-date management of acute and recurrent pericarditis, focusing on the use of anti-inflammatory treatments.
Reinforces anti-inflammatory therapy as pericarditis mainstay; extends prior reviews but leaves optimal regimens open for prospective trials.
Pericarditis refers to the inflammation of the pericardial layers, resulting from a variety of stimuli triggering a stereotyped immune response, and characterized by chest pain associated often with peculiar electrocardiographic changes and, at times, accompanied by pericardial effusion. Acute pericarditis is generally self-limited and not life-threatening; yet, it may cause significant short-term disability, be complicated by either a large pericardial effusion or tamponade, and carry a significant risk of recurrence. The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs. Anti-inflammatory treatments vary, however, in both effectiveness and side-effect profile. The objective of this review is to summarize the up-to-date management of acute and recurrent pericarditis.
No takes yet. Share an insight, caveat, or question.
Chiabrando et al. (2020) conducted a review in Acute and recurrent pericarditis. Anti-inflammatory drugs was evaluated. This review summarizes the up-to-date management of acute and recurrent pericarditis, highlighting anti-inflammatory drugs as the mainstay of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: